A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
The bill’s titles are written by its sponsor.
Apr 18, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.
Senator from Vermont
Read Text »
Last Updated: Apr 18, 2012
Length: 2 pages
This is the first step in the legislative process.
S. 2295 (112th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2295
“S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act.” www.GovTrack.us. 2012. January 21, 2017 <https://www.govtrack.us/congress/bills/112/s2295>
|title=S. 2295 (112th)
|accessdate=January 21, 2017
|author=112th Congress (2012)
|date=April 18, 2012
|quote=Patient Safety and Generic Labeling Improvement Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.